Iria Mendez

Iria Mendez

Auto-generated profile, based on publicly available information

Iria Mendez

11 Servei de Psiquiatria & Psicologia Infantil Juvenil Hospital Universitari Mútua de Terrassa, Fundació Recerca Mútua de Terrassa Terrassa Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2020 in Suicide and Life-Threatening Behavior
Verified
Journal Article
Closed access
PDF file
PPPilar Santamarina Perez
Pilar Santamarina Perez
IMIria Mendez
Iria Mendez
Manpreet K. SinghManpreet K. Singh
Manpreet K. Singh
MBMichele Berk
Michele Berk
MPMarisol Picado
Marisol Picado
SRSoledad Romero
Soledad Romero

1 August 2019 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
PPPilar Santamarina Perez
Pilar Santamarina Perez
SRSoledad Romero
Soledad Romero
IMIria Mendez
Iria Mendez
SLSara M. Leslie
Sara M. Leslie
MPMary M. Packer
Mary M. Packer
MSManpreet K. Singh
Manpreet K. Singh
Objectives: Key neurobiological factors contribute to vulnerability to nonsuicidal self-injury (NSSI) among adolescents and how they respond to treatment targeted to reduce such behaviors. This study aims to examine differences in intrinsic functional connectivity between adolescents with NSSI and healthy controls (HCs) and to identify baseline connectivity markers that predict improvements in NSSI after psychotherapy. Methods: Adolescents aged 12–17 (n = 24) with repetitive NSSI along with demographically similar HCs (n = 16) underwent resting-state functional MRI scanning after which patients received up to 4 months of psychological treatment. A seed-based approach was used to examine baseline between-group differences in intrinsic functional connectivity of the amygdala and the medial prefrontal cortex (mPFC). Further analyses examined the associations between intrinsic functional connectivity at baseline and improvement in NSSI after psychological treatment. Results: Compared with HCs, adolescents with NSSI showed significantly reduced connectivity between the amygdala and the anterior cingulate cortex, subcallosal cortex, and paracingulate gyrus, as well as between the amygdala and a cluster encompassing the right planum temporale and right insula. Adolescents with NSSI, compared with HCs, also showed reduced connectivity between the mPFC and two clusters: one located in the precentral and postcentral gyri and another in the left insula. After treatment, 50% of patients reported fewer NSSI episodes compared to baseline, which was considered as improvement. Stronger negative amygdala-prefrontal connectivity was associated with greater posttreatment improvement in NSSI. Conclusions: Adolescents with NSSI may have aberrant amygdala and mPFC connectivity compared with HCs. Furthermore, stronger baseline negative amygdala-prefrontal connectivity may predict greater improvement in NSSI after psychological intervention. Given that no prior study has used resting-state functional connectivity to predict response to psychological treatment in adolescents with NSSI, replication of these findings is needed.

1 July 2018
Verified
Journal Article
Closed access
DVDaniel Vega
Daniel Vega
ASAnna Sintes
Anna Sintes
MFMarta Fernandez
Marta Fernandez
JPJoaquim Punti
Joaquim Punti
JSJoaquim Soler
Joaquim Soler
JPJuan Carlos Pascual
Juan Carlos Pascual

1 June 2014 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
ABAna Blázquez
Ana Blázquez
SMSergi Mas
Sergi Mas
MPMaria Teresa Plana
Maria Teresa Plana
PGPatricia Gasso
Patricia Gasso
IMIria Méndez
Iria Méndez
LLLuisa Lázaro
Luisa Lázaro
Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents. Despite its efficacy, however, 30% to 40% of patients do not respond to treatment. The aim of this study was to evaluate whether clinical improvement or adverse events are related to the corrected dose of FLX at 8 and 12 weeks after starting treatment in a sample of adolescents diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. Seventy-four subjects aged between 10 and 17 years participated in the study. Clinical improvement was measured with the Clinical Global Impression-Improvement Scale, whereas the UKU (Udvalg for Klinske Undersogelser) scale was administered to assess adverse effects of treatment. Fluoxetine per kilograms of body weight was related to serum concentration of FLX, NORFLX (norfluoxetine), FLX + NORFLX, and FLX/NORFLX. No relationship was found between dose-corrected FLX levels and therapeutic or adverse effects. No differences in serum concentrations were found between responders and nonresponders to treatment. Sex differences were observed in relation to dose and FLX serum concentration. The analysis by diagnosis revealed differences in FLX dose between obsessive-compulsive disorder patients and both generalized anxiety disorder and major depressive disorder patients. Fluoxetine response seems to be influenced by factors such as sex, diagnosis, or certain genes that might be involved in the drug's pharmacokinetics and pharmacodynamics. Clinical and pharmacogenetic studies are needed to elucidate further the differences between treatment responders and nonresponders.

13 December 2016 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
TCthe STOP consortium
the STOP consortium
IFItziar Flamarique Flamarique
Itziar Flamarique Flamarique
PSParamala Santosh
Paramala Santosh
AZalessandro zuddas
alessandro zuddas
CAC. Arango
C. Arango
JCJosefina Castro-Fornieles
Josefina Castro-Fornieles
To create a self-reported, internet-based questionnaire for the assessment of suicide risk in children and adolescents. As part of the EU project ‘Suicidality: Treatment Occurring in Paediatrics’ (STOP project), we developed web-based Patient Reported Outcome Measures (PROMs) for children and adolescents and for proxy reports by parents and clinicians in order to assess suicidality. Based on a literature review, expert panels and focus groups of patients, we developed the items of the STOP Suicidality Assessment Scale (STOP-SAS) in Spanish and English, translated it into four more languages, and optimized it for web-based presentation using the HealthTrackerTM platform. Of the total 19 questions developed for the STOP-SAS, four questions that assess low-level suicidality were identified as screening questions (three of them for use with children, and all four for use with adolescents, parents and clinicians). A total of 395 adolescents, 110 children, 637 parents and 716 clinicians completed the questionnaire using the HealthTrackerTM, allowing us to evaluate the internal consistency and convergent validity of the STOP-SAS with the clinician-rated Columbia Suicide Severity Rating Scale (C-SSRS). Validity was also assessed with the receiver operating characteristic (ROC) area of the STOP-SAS with the C-SSRS. The STOP-SAS comprises 19 items in its adolescent, parent, and clinician versions, and 14 items in its children’s version. Good internal consistency was found for adolescents (Cronbach’s alpha: 0.965), children (Cronbach’s alpha: 0.922), parents (Cronbach’s alpha: 0.951) and clinicians (Cronbach’s alpha: 0.955) versions. A strong correlation was found between the STOP-SAS and the C-SSRS for adolescents (r:0.670), parents (r:0.548), clinicians (r:0.863) and children (r:0.654). The ROC area was good for clinicians’ (0.917), adolescents’ (0.834) and parents’ (0.756) versions but only fair (0.683) for children’s version. The STOP-SAS is a comprehensive, web-based PROM developed on the HealthTrackerTM platform, and co-designed for use by adolescents, children, parents and clinicians. It allows the evaluation of aspects of suicidality and shows good reliability and validity.

3 January 2010 in European Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
TPTeresa Plana
Teresa Plana
RGR. Gracia
R. Gracia
IMI. Méndez
I. Méndez
LPL. Pintor
L. Pintor
LLL. Lazaro
L. Lazaro
JCJ. Castro-Fornieles
J. Castro-Fornieles